Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

461 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.
Oseledchyk A, Ricca JM, Gigoux M, Ko B, Redelman-Sidi G, Walther T, Liu C, Iyer G, Merghoub T, Wolchok JD, Zamarin D. Oseledchyk A, et al. Among authors: iyer g. Oncotarget. 2018 Jun 19;9(47):28702-28716. doi: 10.18632/oncotarget.25614. eCollection 2018 Jun 19. Oncotarget. 2018. PMID: 29983890 Free PMC article.
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
Snyder A, Nathanson T, Funt SA, Ahuja A, Buros Novik J, Hellmann MD, Chang E, Aksoy BA, Al-Ahmadie H, Yusko E, Vignali M, Benzeno S, Boyd M, Moran M, Iyer G, Robins HS, Mardis ER, Merghoub T, Hammerbacher J, Rosenberg JE, Bajorin DF. Snyder A, et al. Among authors: iyer g. PLoS Med. 2017 May 26;14(5):e1002309. doi: 10.1371/journal.pmed.1002309. eCollection 2017 May. PLoS Med. 2017. PMID: 28552987 Free PMC article. Clinical Trial.
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, Cipolla CK, Bluth MJ, Chaim J, Al-Ahmadie H, Snyder A, Carlo MI, Solit DB, Berger MF, Funt S, Wolchok JD, Iyer G, Bajorin DF, Callahan MK, Rosenberg JE. Teo MY, et al. Among authors: iyer g. J Clin Oncol. 2018 Jun 10;36(17):1685-1694. doi: 10.1200/JCO.2017.75.7740. Epub 2018 Feb 28. J Clin Oncol. 2018. PMID: 29489427 Free PMC article. Clinical Trial.
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT. Samstein RM, et al. Among authors: iyer g. Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14. Nat Genet. 2019. PMID: 30643254 Free PMC article.
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.
Shen R, Postow MA, Adamow M, Arora A, Hannum M, Maher C, Wong P, Curran MA, Hollmann TJ, Jia L, Al-Ahmadie H, Keegan N, Funt SA, Iyer G, Rosenberg JE, Bajorin DF, Chapman PB, Shoushtari AN, Betof AS, Momtaz P, Merghoub T, Wolchok JD, Panageas KS, Callahan MK. Shen R, et al. Among authors: iyer g. Sci Transl Med. 2021 Aug 25;13(608):eabf5107. doi: 10.1126/scitranslmed.abf5107. Sci Transl Med. 2021. PMID: 34433638 Free PMC article.
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.
Holm JS, Funt SA, Borch A, Munk KK, Bjerregaard AM, Reading JL, Maher C, Regazzi A, Wong P, Al-Ahmadie H, Iyer G, Tamhane T, Bentzen AK, Herschend NO, De Wolf S, Snyder A, Merghoub T, Wolchok JD, Nielsen M, Rosenberg JE, Bajorin DF, Hadrup SR. Holm JS, et al. Among authors: iyer g. Nat Commun. 2022 Apr 11;13(1):1935. doi: 10.1038/s41467-022-29342-0. Nat Commun. 2022. PMID: 35410325 Free PMC article. Clinical Trial.
CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract.
Gupta S, Vanderbilt CM, Zhang Y, Tickoo SK, Fine SW, Gopalan A, Chen YB, Sirintrapun SJ, Teo MY, Funt SA, Iyer G, Rosenberg JE, Bajorin DF, Bochner BH, Pietzak EJ, Ross DS, Ladanyi M, Cheville JC, Solit DB, Reuter VE, Al-Ahmadie HA. Gupta S, et al. Among authors: iyer g. Bladder Cancer. 2021;7(4):395-400. doi: 10.3233/blc-201532. Epub 2021 Dec 13. Bladder Cancer. 2021. PMID: 35071713 Free PMC article.
Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
Vanguri RS, Smithy JW, Li Y, Zhuang M, Maher CA, Aleynick N, Peng X, Al-Ahmadie H, Funt SA, Rosenberg JE, Iyer G, Bajorin D, Mathews JC, Nadeem S, Panageas KS, Shen R, Callahan MK, Hollmann TJ. Vanguri RS, et al. Among authors: iyer g. J Pathol. 2023 Nov;261(3):349-360. doi: 10.1002/path.6197. Epub 2023 Sep 5. J Pathol. 2023. PMID: 37667855
461 results